Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection

Helicobacter

Volumn 11, Issue 5, 2006, Pages 436-440

  Murakami, Kazunari ^a   Okimoto, Tadayoshi ^a   Kodama, Masaaki ^a   Sato, Ryugo ^a   Miyajima, Hajime ^a   Ono, Masami ^a   Inoue, Kunimitsu ^a   Watanabe, Koichiro ^a   Otsu, Satoshi ^a   Fujioka, Toshio ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Clarithromycin; Drug resistance; Famotidine; H. pylori; H2 receptor antagonist; Lansoprazole; Metronidazole; Proton pump inhibitor; Second line eradication

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FAMOTIDINE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; METRONIDAZOLE; MIDDLE AGED; PROTON PUMPS; TREATMENT FAILURE;

HELICOBACTER PYLORI;

EID: 33748441770     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2006.00435.x     Document Type: Article

References (27)

1. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
2. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. Infect Dis 1990;161:626-33.
3. Nagahara A, Miwa H, Ohkura R, Yamada T, Sato K, Hojo M, Sato N. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepato 2001;16:613-8.
4. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, Protons, and Helicobacter pylori. Yale J Biol Med 1996;9:301-16.
5. Wang DP, Yeh MK. Degradation Kinetics of Metronidazole in Solution. J Pharm Sci 1993;82:95-8.
6. Chassany O, Bergmann JF, Simoneau G, Elouaer-Blanc L, Segrestaa JM, Caulin C. The comparative effects of single intravenous doses of cimetidine, ranitidine, famotidine, and omeprazole on intragastric pH. Current Ther Res 1996;57:159-67.
7. Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001;6:177-86.
8. Murakami K, Okimoto T, Sato R, Nasu M, Kodama M, Fujioka T. The resistance of Helicobacter pylori and problems in Japan (In Japanese). Helicobacter Res 2003;7:117-20.
9. Vakil N, Hahn B, McSoley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998;93:1423-35.
10. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxycillin: influence on treatment outcome. Am J Gastroenterol 1998;93:386-9.
11. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J, Sato S, Abe H, Arita T. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002;16:1933-8.
12. Laine L, Suchower L, Frantz J, Connors A, Neil G. Low rate emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. Aliment Pharmacol Ther 1998;12:887-92.
13. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002;19:67-70.
14. Hoshiya S, Watanabe K, Tokunaga K et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 2000;35:10-4.
15. Goh KL, Parasakthi N, Chuah SY, Toetsch M. Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori - a randomized, double-blind comparison of a three times daily and twice daily regimen. Eur J Gastroenterol Hepatol 1997;9:1091-5.
16. Gschwantler M, Dragosics B, Wurzer H, Brandstätter G, Weiss W. Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxycillin and clarithromycin. Eur J Gastroenterol Hepatol 1998;10:579-82.
17. Gschwantler M, Dragosics B, Schütze K, et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori-a randomized, controlled trial. Aliment Pharmacol Ther 1999;13:1063-9.
18. Hsu CC, Chen JJ, Hu TH, Lu SN, Changchien CS. Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001;13:921-6.
19. 2-receptor antagonist and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer. J Intern Medical Res 2003;31:469-74.
20. 2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36.
21. 2-receptor antagonist, vs. lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 2003;8:111-9.
22. 2-receptor antagonist. (in Jap) Nipponrinsho 1999;57:148-52.
23. Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, Ishizaki T. Comparision of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype. Aliment Pharmacol Ther 2002;16:837-46.
24. Morii M, Takata H, Takeguchi N. Acid activation of omeprazole in isolated gastric vesicles, oxyntic cells, and gastric glands. Gastroenterology 1989;96:1453-61.
25. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
26. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005;100:1037-42.
27. Azuma T, Yamazaki S, Yamakawa A, et al. Association between diversity in the srchomology domain-containing tyrosine phosphatase biding site of Helicobacter pylori CagA protein and gastric atrophy and gastric atrophy and cancer. J Infect Dis 2004;189:820-7.